TRIM52 and hepatocellular carcinoma: In other cancers, TRIM7 can suppress hepatocellular carcinoma progression (Zhu et al., 2020), while an oncogenic function was reported in colorectal cancer (Cao et al., 2019) and pancreatic cancer (Sun et al., 2020) for TRIM2 and in hepatocellular carcinoma for TRIM52-AS1 (Zhou et al., 2021).